Trial Profile

A Phase 1 Study of GRN163L (Imetelstat) in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia That is in Second or Greater Relapse or That is Refractory to Relapse Therapy; Myelodysplastic Syndrome or Juvenile Myelomonocytic Leukemia in First or Greater Relapse or is Refractory to Relapse Therapy

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 20 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cytarabine (Primary) ; Cytarabine (Primary) ; Fludarabine (Primary) ; Folinic acid (Primary) ; Folinic acid (Primary) ; Hydrocortisone (Primary) ; Imetelstat (Primary) ; Methotrexate (Primary)
Indications Acute myeloid leukaemia; Juvenile myelomonocytic leukaemia; Myelodysplastic syndromes
Focus Adverse reactions

10 Dec 2024 Trial design presented at the 66th American Society of Hematology Annual Meeting and Exposition.
25 Sep 2024 Planned End Date changed from 1 Apr 2026 to 30 Jun 2026.
25 Sep 2024 Planned primary completion date changed from 1 Apr 2026 to 30 Jun 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com